308 related articles for article (PubMed ID: 25944486)
1. Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy.
Bosch-Barrera J; Menendez JA
Cancer Treat Rev; 2015 Jun; 41(6):540-6. PubMed ID: 25944486
[TBL] [Abstract][Full Text] [Related]
2. Targeting STAT3 with silibinin to improve cancer therapeutics.
Bosch-Barrera J; Queralt B; Menendez JA
Cancer Treat Rev; 2017 Jul; 58():61-69. PubMed ID: 28686955
[TBL] [Abstract][Full Text] [Related]
3. Silibinin--a promising new treatment for cancer.
Cheung CW; Gibbons N; Johnson DW; Nicol DL
Anticancer Agents Med Chem; 2010 Mar; 10(3):186-95. PubMed ID: 20015009
[TBL] [Abstract][Full Text] [Related]
4. Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.
Polachi N; Bai G; Li T; Chu Y; Wang X; Li S; Gu N; Wu J; Li W; Zhang Y; Zhou S; Sun H; Liu C
Eur J Med Chem; 2016 Nov; 123():577-595. PubMed ID: 27517806
[TBL] [Abstract][Full Text] [Related]
5. Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells.
Agarwal C; Tyagi A; Kaur M; Agarwal R
Carcinogenesis; 2007 Jul; 28(7):1463-70. PubMed ID: 17341659
[TBL] [Abstract][Full Text] [Related]
6. Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells.
Cufí S; Bonavia R; Vazquez-Martin A; Corominas-Faja B; Oliveras-Ferraros C; Cuyàs E; Martin-Castillo B; Barrajón-Catalán E; Visa J; Segura-Carretero A; Bosch-Barrera J; Joven J; Micol V; Menendez JA
Food Chem Toxicol; 2013 Oct; 60():360-8. PubMed ID: 23916468
[TBL] [Abstract][Full Text] [Related]
7. Targeting silibinin in the antiproliferative pathway.
Li L; Zeng J; Gao Y; He D
Expert Opin Investig Drugs; 2010 Feb; 19(2):243-55. PubMed ID: 20047507
[TBL] [Abstract][Full Text] [Related]
8. Induction of fibronectin in response to epidermal growth factor is suppressed by silibinin through the inhibition of STAT3 in triple negative breast cancer cells.
Kim S; Jeon M; Lee J; Han J; Oh SJ; Jung T; Nam SJ; Kil WH; Lee JE
Oncol Rep; 2014 Nov; 32(5):2230-6. PubMed ID: 25175149
[TBL] [Abstract][Full Text] [Related]
9. Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells.
Byun HJ; Darvin P; Kang DY; Sp N; Joung YH; Park JH; Kim SJ; Yang YM
Oncol Rep; 2017 Jun; 37(6):3270-3278. PubMed ID: 28440514
[TBL] [Abstract][Full Text] [Related]
10. Silibinin and its 2,3-dehydro-derivative inhibit basal cell carcinoma growth via suppression of mitogenic signaling and transcription factors activation.
Tilley C; Deep G; Agarwal C; Wempe MF; Biedermann D; Valentová K; Kren V; Agarwal R
Mol Carcinog; 2016 Jan; 55(1):3-14. PubMed ID: 25492239
[TBL] [Abstract][Full Text] [Related]
11. Silibinin is a direct inhibitor of STAT3.
Verdura S; Cuyàs E; Llorach-Parés L; Pérez-Sánchez A; Micol V; Nonell-Canals A; Joven J; Valiente M; Sánchez-Martínez M; Bosch-Barrera J; Menendez JA
Food Chem Toxicol; 2018 Jun; 116(Pt B):161-172. PubMed ID: 29660364
[TBL] [Abstract][Full Text] [Related]
12. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer.
Flaig TW; Glodé M; Gustafson D; van Bokhoven A; Tao Y; Wilson S; Su LJ; Li Y; Harrison G; Agarwal R; Crawford ED; Lucia MS; Pollak M
Prostate; 2010 Jun; 70(8):848-55. PubMed ID: 20127732
[TBL] [Abstract][Full Text] [Related]
13. Silibinin triggers apoptotic signaling pathways and autophagic survival response in human colon adenocarcinoma cells and their derived metastatic cells.
Kauntz H; Bousserouel S; Gossé F; Raul F
Apoptosis; 2011 Oct; 16(10):1042-53. PubMed ID: 21779837
[TBL] [Abstract][Full Text] [Related]
14. Silibinin inhibits expression of HIF-1alpha through suppression of protein translation in prostate cancer cells.
Jung HJ; Park JW; Lee JS; Lee SR; Jang BC; Suh SI; Suh MH; Baek WK
Biochem Biophys Res Commun; 2009 Dec; 390(1):71-6. PubMed ID: 19778521
[TBL] [Abstract][Full Text] [Related]
15. Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin.
Bosch-Barrera J; Sais E; Cañete N; Marruecos J; Cuyàs E; Izquierdo A; Porta R; Haro M; Brunet J; Pedraza S; Menendez JA
Oncotarget; 2016 May; 7(22):32006-14. PubMed ID: 26959886
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells.
Tyagi A; Bhatia N; Condon MS; Bosland MC; Agarwal C; Agarwal R
Prostate; 2002 Nov; 53(3):211-7. PubMed ID: 12386921
[TBL] [Abstract][Full Text] [Related]
17. The milk thistle (Silybum marianum) compound Silibinin stimulates leukopoiesis from mouse embryonic stem cells.
Sharifpanah F; Ali EH; Wartenberg M; Sauer H
Phytother Res; 2019 Feb; 33(2):452-460. PubMed ID: 30548344
[TBL] [Abstract][Full Text] [Related]
18. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells.
Davis-Searles PR; Nakanishi Y; Kim NC; Graf TN; Oberlies NH; Wani MC; Wall ME; Agarwal R; Kroll DJ
Cancer Res; 2005 May; 65(10):4448-57. PubMed ID: 15899838
[TBL] [Abstract][Full Text] [Related]
19. Preventive effect of silymarin in cerebral ischemia-reperfusion-induced brain injury in rats possibly through impairing NF-κB and STAT-1 activation.
Hou YC; Liou KT; Chern CM; Wang YH; Liao JF; Chang S; Chou YH; Shen YC
Phytomedicine; 2010 Oct; 17(12):963-73. PubMed ID: 20833521
[TBL] [Abstract][Full Text] [Related]
20. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels.
Singh RP; Dhanalakshmi S; Tyagi AK; Chan DC; Agarwal C; Agarwal R
Cancer Res; 2002 Jun; 62(11):3063-9. PubMed ID: 12036915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
